Abstract:Cancer-associated fibroblasts (CAFs) exhibit remarkable phenotypic heterogeneity, with specific subsets implicated in immunosuppression in various malignancies. However, whether and how they attenuate anti-tumor immunity in gastric cancer (GC) remains elusive. CPT1C, a unique isoform of carnitine palmitoyltransferase pivotal in regulating fatty acid oxidation, is briefly indicated as a protumoral metabolic mediator in the tumor microenvironment (TME) of GC. In the present study, we initially identified specific subsets of fibroblasts exclusively overexpressing CPT1C, hereby termed them as CPT1C + CAFs. Subsequent findings indicated that CPT1C + CAFs fostered a stroma-enriched and immunosuppressive TME as they correlated with extracellular matrix-related molecular features and enrichment of both immunosuppressive subsets, especially M2-like macrophages, and multiple immune-related pathways. Next, we identified that CPT1C + CAFs promoted the M2-like phenotype of macrophage in vitro . Bioinformatic analyses unveiled the robust IL-6 signaling between CPT1C + CAFs and M2-like phenotype of macrophage and identified CPT1C + CAFs as the primary source of IL-6. Meanwhile, suppressing CPT1C expression in CAFs significantly decreased IL-6 secretion in vitro . Lastly, we demonstrated the association of CPT1C + CAFs with therapeutic resistance. Notably, GC patients with high CPT1C + CAFs infiltration responded poorly to immunotherapy in clinical cohort. Collectively, our data not only present the novel identification of CPT1C + CAFs as immunosuppressive subsets in TME of GC, but also reveal the underlying mechanism that CPT1C + CAFs impair tumor immunity by secreting IL-6 to induce the immunosuppressive M2-like phenotype of macrophage in GC.

What problem does this paper attempt to address?

The problem this paper attempts to address is how cancer-associated fibroblasts (CAFs) in gastric cancer (GC) influence the anti-tumor immune response in the tumor microenvironment (TME) by promoting the formation of immunosuppressive M2-like macrophages. Specifically, the researchers identified a specific subset of CAFs—CPT1C-positive CAFs (CPT1C+CAFs)—which promote the formation of M2-like macrophages by secreting IL-6, leading to an immunosuppressive TME. Additionally, the study explored the role of CPT1C+CAFs in the response of gastric cancer patients to adjuvant chemotherapy and immunotherapy. ### Summary of Main Issues: 1. **Identification and Characteristics of CPT1C+CAFs**: The study first identified a subset of CAFs that specifically overexpress CPT1C in gastric cancer (CPT1C+CAFs) and explored their role in the tumor microenvironment. 2. **Impact of CPT1C+CAFs on TME**: The study found that CPT1C+CAFs can promote the formation of a stroma-rich and immunosuppressive TME. 3. **Relationship Between CPT1C+CAFs and M2-like Macrophages**: The study revealed that CPT1C+CAFs promote the formation of M2-like macrophages by secreting IL-6, thereby affecting the anti-tumor immune response. 4. **Relationship Between CPT1C+CAFs and Treatment Response**: The study analyzed the role of CPT1C+CAFs in the response of gastric cancer patients to adjuvant chemotherapy and immunotherapy, finding that patients with high CPT1C+CAFs infiltration had a poorer response to these treatments. ### Significance of the Study: - **Identification of a New Subset**: The identification of CPT1C+CAFs as a new subset of CAFs provides a new perspective for understanding the immunosuppressive mechanisms in gastric cancer. - **Mechanism Elucidation**: The detailed elucidation of the mechanism by which CPT1C+CAFs promote the formation of M2-like macrophages by secreting IL-6 provides a theoretical basis for developing new therapeutic strategies. - **Potential for Clinical Application**: The study results suggest that CPT1C+CAFs may be a potential biomarker for the response of gastric cancer patients to adjuvant chemotherapy and immunotherapy, aiding in the selection of personalized treatment plans. By addressing these issues, this study not only deepens the understanding of the immune microenvironment in gastric cancer but also provides new directions for future therapeutic strategies.

CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage